Ifrah Financial Services Inc. Invests $454,000 in Halozyme Therapeutics, Inc. $HALO

Ifrah Financial Services Inc. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,029 shares of the biopharmaceutical company’s stock, valued at approximately $454,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Measured Wealth Private Client Group LLC grew its position in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Clearstead Advisors LLC boosted its stake in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Finally, Wexford Capital LP bought a new stake in shares of Halozyme Therapeutics during the third quarter worth $70,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HALO has been the subject of a number of research analyst reports. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $81.60.

Insider Activity

In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director owned 43,669 shares in the company, valued at $2,891,324.49. The trade was a 3.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,250 shares of company stock worth $6,299,746 in the last ninety days. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Trading Up 0.0%

HALO stock opened at $74.96 on Monday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The company has a market cap of $8.89 billion, a P/E ratio of 26.96, a PEG ratio of 0.31 and a beta of 0.88. The business has a fifty day moving average of $68.42 and a 200-day moving average of $68.90.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.